Goldman Sachs Group Inc Nymox Pharmaceutical Corp Transaction History

Goldman Sachs Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 May 14, 2024	BUY	$0.19 - $0.49 $399 - $1,029	2,100 Added 10.51%	22,084 $4,000
Q2 2023 Aug 14, 2023	BUY	$0.19 - $0.49 $399 - $1,029	2,100 Added 10.51%	22,084 $4,000
Q4 2022 May 14, 2024	SELL	$0.28 - $0.74 $346 - $916	-1,238 Reduced 5.83%	19,984 $6,000
Q4 2022 Feb 13, 2023	SELL	$0.28 - $0.74 $346 - $916	-1,238 Reduced 5.83%	19,984 $6,000
Q3 2022 May 14, 2024	SELL	$0.22 - $0.61 $563 - $1,561	-2,560 Reduced 10.76%	21,222 $9,000
Q3 2022 Nov 10, 2022	SELL	$0.22 - $0.61 $563 - $1,561	-2,560 Reduced 10.76%	21,222 $0
Q2 2022 May 14, 2024	BUY	$0.38 - $1.41 $9,037 - $33,532	23,782 New	23,782 $10,000
Q2 2022 Aug 15, 2022	SELL	$0.38 - $1.41 $46 - $173	-123 Reduced 0.51%	23,782 $10,000
Q1 2022 May 16, 2022	SELL	$1.21 - $2.0 $577 - $954	-477 Reduced 1.96%	23,905 $30,000
Q4 2021 Feb 14, 2022	BUY	$0.95 - $2.1 $0 - $2	1 Added 0.0%	24,382 $32,000
Q3 2021 Nov 10, 2021	BUY	$1.3 - $2.23 $31,695 - $54,369	24,381 New	24,381 $50,000

150K

Ticker NYMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,265,000
Market Cap $42.9M
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.